DISCLAIMERS
The information provided above is general reimbursement information for LUMASON. It is not legal advice, nor is it advice about how to code, complete, or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider’s responsibility to determine and submit appropriate codes, charges, modifiers, and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.

CPT® copyright 2016 American Medical Association (AMA). All rights reserved. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.
CONTENTS

What’s new in 2017? HOPPS .................................................................................................................................3
- Summary of 2017 Imaging APCs ..........................................................................................................................3
- 2016 APCs vs 2017 APCs (Echocardiography) ........................................................................................................4
- 2016 APCs vs 2017 APCs (Ultrasonography of the liver and urinary tract) ...............................................................5

LUMASON Pass-Through Payment—HOPPS ...............................................................................................................6
- Sample hospital setting billing form UB-04 CMS-1450 ..........................................................................................7

LUMASON indications ..................................................................................................................................................8

Coding ............................................................................................................................................................................9
- CPT® & HCPCS codes ..............................................................................................................................................10
- Medicare National Payment Rates for HOPPS (Echocardiography HCPCS C-code series for Medicare) ..........11
- Medicare National Payment Rates for HOPPS (Echocardiography CPT® codes for non-Medicare and commercial payers) .................................................................................................................................................12
- Medicare National Payment Rates for HOPPS (Ultrasonography of the liver and urinary tract) ............................13
- Echocardiography: Cross Walk Codes Without and With Contrast ........................................................................13
- Medicare National Average Payment for physicians office & IDTFs ........................................................................14

Physician office & IDTF billing ......................................................................................................................................15
- Sample physician billing global non-hospital outpatient setting CMS-1500 ..........................................................16

Hospital in-patient billing .............................................................................................................................................17

Coverage .......................................................................................................................................................................17

Reimbursement Hotline ..............................................................................................................................................18

LUMASON Ordering Information ..................................................................................................................................19
WHAT’S NEW IN 2017? HOPPS

**Significant restructuring of APCs²**

In 2017, the APC structure used in radiology, echocardiography, and ultrasound services was consolidated from 17 codes to only 7 codes. A detailed description of changes in procedure APC coding from 2016 to 2017 can be found on pages 4 and 5.

Summary of 2017 imaging APCs³

<table>
<thead>
<tr>
<th>Final CY 2017 Imaging APCs</th>
<th>APC</th>
<th>2017 payment levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1 Imaging without Contrast</td>
<td>5521</td>
<td>$59.86</td>
</tr>
<tr>
<td>Level 2 Imaging without Contrast</td>
<td>5522</td>
<td>$112.73</td>
</tr>
<tr>
<td>Level 3 Imaging without Contrast</td>
<td>5523</td>
<td>$225.91</td>
</tr>
<tr>
<td>Level 4 Imaging without Contrast</td>
<td>5524</td>
<td>$449.68</td>
</tr>
<tr>
<td>Level 1 Imaging with Contrast</td>
<td>5571</td>
<td>$265.02</td>
</tr>
<tr>
<td>Level 2 Imaging with Contrast</td>
<td>5572</td>
<td>$426.52</td>
</tr>
<tr>
<td>Level 3 Imaging with Contrast</td>
<td>5573</td>
<td>$656.91</td>
</tr>
</tbody>
</table>

APC=Ambulatory Payment Classification; HOPPS=Hospital Outpatient Prospective Payment System.

**INDICATIONS AND USAGE¹**

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS¹**

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

**IMPORTANT SAFETY INFORMATION¹**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].³


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
2016 APCs vs 2017 APCs

<table>
<thead>
<tr>
<th>HCPCS/ CPT codes</th>
<th>Short descriptor</th>
<th>APC 2016</th>
<th>APC 2016 description</th>
<th>New APC 2017</th>
<th>APC 2017 description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93303</td>
<td>Echo transthoracic</td>
<td>5534</td>
<td>Ultrasound &amp; related services level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93304</td>
<td>Echo transthoracic</td>
<td>5533</td>
<td>Ultrasound &amp; related services level 3</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93306</td>
<td>TTE w/doppler complete</td>
<td>5533</td>
<td>Ultrasound &amp; related services Level 3</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93307</td>
<td>TTE w/o doppler complete</td>
<td>5533</td>
<td>Ultrasound &amp; related services Level 3</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93308</td>
<td>TTE f-up or ltd</td>
<td>5532</td>
<td>Ultrasound &amp; related services Level 2</td>
<td>5523</td>
<td>Level 3 Imaging without contrast</td>
</tr>
<tr>
<td>93312</td>
<td>Echo transesophageal</td>
<td>5534</td>
<td>Ultrasound &amp; related services Level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93313</td>
<td>Echo transesophageal</td>
<td>5534</td>
<td>Ultrasound &amp; related services Level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93315</td>
<td>Echo transesophageal</td>
<td>5534</td>
<td>Ultrasound &amp; related services Level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93316</td>
<td>Echo transesophageal</td>
<td>5534</td>
<td>Ultrasound &amp; related services Level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93318</td>
<td>Echo transesophageal intraop</td>
<td>5534</td>
<td>Ultrasound &amp; related services Level 4</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93350</td>
<td>Stress TTE only</td>
<td>5533</td>
<td>Ultrasound &amp; related services Level 3</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>93351</td>
<td>Stress TTE complete</td>
<td>5533</td>
<td>Ultrasound &amp; related services Level 3</td>
<td>5524</td>
<td>Level 4 Imaging without contrast</td>
</tr>
<tr>
<td>C8921</td>
<td>TTE w or w/o fol w/cont, com</td>
<td>5562</td>
<td>Ultrasound &amp; related services Level 3</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8922</td>
<td>TTE w or w/o fol w/cont, fu</td>
<td>5561</td>
<td>Echo with contrast- level 1</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8923</td>
<td>2d TTE w or w/o fol w/cont, co</td>
<td>5561</td>
<td>Echo with contrast- level 1</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8924</td>
<td>2d TTE w or w/o fol w/cont, fu</td>
<td>5561</td>
<td>Echo with contrast- level 1</td>
<td>5572</td>
<td>Level 2 Imaging with contrast</td>
</tr>
<tr>
<td>C8925</td>
<td>2d TEE w or w/o fol w/cont, in</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8926</td>
<td>TEE w or w/o fol w/cont, cong</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8927</td>
<td>TEE w or w/o fol w/cont, mon</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8928</td>
<td>TTE w or w/o fol w/cont, stres</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8929</td>
<td>TTE w or w/o fol w/con, doppler</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
<tr>
<td>C8930</td>
<td>TTE w or w/o cont, cont ecg</td>
<td>5562</td>
<td>Echo with contrast- level 2</td>
<td>5573</td>
<td>Level 3 Imaging with contrast</td>
</tr>
</tbody>
</table>

**INDICATIONS AND USAGE**

LUMASON is an ultrasound contrast agent indicated for use:
- In echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- In ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- In ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS**

LUMASON is contraindicated in patients with:
- History of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

**IMPORTANT SAFETY INFORMATION**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. [See Warnings and Precautions (5.1)].

Most serious reactions occur within 30 minutes of administration. [See Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration. [See Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available. [See Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias). [See Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
**WHAT’S NEW IN 2017? HOPPS (cont’d)**

<table>
<thead>
<tr>
<th>2016 APCs vs 2017 APCs (cont’d)¹</th>
<th>HCPCS/CPT® codes</th>
<th>Short descriptor</th>
<th>APC 2016</th>
<th>APC 2016 description</th>
<th>New APC 2017</th>
<th>APC 2017 description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ultrasonography of the liver</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C9744</td>
<td>Ultrasound of abdomen with contrast - new Oct. 1, 2016³</td>
<td>5571</td>
<td>Level 1 CT with contrast &amp; CT angiography</td>
<td>5571</td>
<td>Level 1 Imaging with contrast</td>
<td></td>
</tr>
<tr>
<td>76700</td>
<td>Ultrasound of abdomen complete</td>
<td>5532</td>
<td>Ultrasound &amp; related services level 2</td>
<td>5522</td>
<td>Level 2 Imaging without contrast</td>
<td></td>
</tr>
<tr>
<td>76705</td>
<td>Ultrasound of abdomen limited</td>
<td>5532</td>
<td>Ultrasound &amp; related services level 2</td>
<td>5522</td>
<td>Level 2 Imaging without contrast</td>
<td></td>
</tr>
<tr>
<td><strong>Ultrasonography of the urinary tract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C9744</td>
<td>Ultrasound of abdomen with contrast - updated March 3, 2017⁵</td>
<td>5571</td>
<td>Level 1 CT with contrast &amp; CT angiography</td>
<td>5571</td>
<td>Level 1 Imaging with contrast</td>
<td></td>
</tr>
<tr>
<td>76770</td>
<td>Ultrasound retroperitoneal, complete</td>
<td>5532</td>
<td>Ultrasound &amp; related services level 2</td>
<td>5522</td>
<td>Level 2 Imaging without contrast</td>
<td></td>
</tr>
<tr>
<td>76775</td>
<td>Ultrasound, retroperitoneal, limited</td>
<td>5532</td>
<td>Ultrasound &amp; related services level 2</td>
<td>5522</td>
<td>Level 2 Imaging without contrast</td>
<td></td>
</tr>
</tbody>
</table>

**New HCPCS C-code for ultrasound, abdominal with contrast—Code C9744⁵**


**INDICATIONS AND USAGE¹**

LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS¹**

LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

**IMPORTANT SAFETY INFORMATION¹**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].¹


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
LUMASON has Pass-Through payment status
Payment in an outpatient hospital clinic is based on a prospective payment system. The system is based on groups of procedures, medical visits, and ancillary services. Under the HOPPS system, contrast agents are not separately payable; rather, they are packaged into the APCs for the procedure with which they are utilized.

However, there is an exception in the case of LUMASON, because of its Pass-Through payment status. A Pass-Through payment status means that a temporary additional HOPPS payment is made for innovative devices, drugs, and biologicals for Medicare beneficiaries. It is not subject to coinsurance or packaging rules. LUMASON Pass-Through payment value is updated quarterly: go to Medicare Addendum B—code Q9950 for the current reimbursement: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1656-CN.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1656-CN.html).

It is important to code Q9950 and all the mL used and discarded for a total of 5 mL to benefit from the Pass-Through payment along with the specific procedure performed, and effective January 1, 2017, Medicare requires the use of the JW modifier to indicate the amount of discarded drug/product from a single-use vial. For more information: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf).

To find out which APC is applicable to the procedure code, please refer to the 2016 APCs vs 2017 APCs chart under the What’s new in 2017? HOPPS section of this guide.

INDICATIONS AND USAGE
LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the leftventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS
LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
**LUMASON Pass-Through Payment—HOPPS (cont’d)**

**Sample hospital setting billing form UB-04 CMS-1450**

**Echocardiography with LUMASON**

**WARNING:** SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

**INDICATIONS AND USAGE**

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients

**CONTRAINDICATIONS**

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
LUMASON INDICATIONS

LUMASON is the only ultrasound contrast agent with 3 indications and Pass-Through payment status.

✓ Echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms

✓ Ultrasonography of the liver for the characterization of focal liver lesions in adult and pediatric patients

NEW—On Dec. 22, 2016, LUMASON received FDA approval for:

✓ Ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

INDICATIONS AND USAGE

LUMASON is an ultrasound contrast agent indicated for use:

• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON is contraindicated in patients with:

• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Please see full Prescribing Information including boxed WARNING at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason-prescribing-information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Using the correct codes is the first step to support correct reimbursement

Procedures must be coded correctly in order to obtain appropriate reimbursement from both CMS and commercial payers. The following describes the types of codes that may be applied when submitting claims for echocardiography, ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients, or ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients.

CPT®
Codes used to report the service or procedure performed.

HCPCS
Codes used to report the provision of supplies, materials, injections, and certain services and procedures. For example, the HCPCS code for LUMASON is Q0950.

C-codes
Unique, temporary HCPCS codes created by Medicare and used for HOPPS only. This is often done when no other appropriate code exists. An example of this is the C-code series in echocardiography, which are described on page 11, and the new C-code for ultrasound of the abdomen with contrast: C9744.

ICD-10 (International Classification of Disease)
Codes used to describe a patient's signs and symptoms that would represent a medically necessary reason for performing the procedure. ICD-10 codes need to be entered on the claim form.

APC
This is the payment system of HOPPS. A summary chart of the changes in 2017 with the new APCs is included on pages 4 and 5 of this guide.

NDC (National Drug Code)
An NDC code provides a unique identifier for a specific drug. The NDC for LUMASON is: 0270-7099-16.

Medicare Addendum B
These files are updated quarterly and reflect hospital HOPPS payment rates for HCPCS codes and APC codes. This is also where the Pass-Through code for LUMASON (Q0950) can be found: www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/HospitalOutpatientPps/Addendum-A-and-Addendum-B-Updates.html.

Medicare Part B ASP (average selling price) file
Quarterly payment files are published for independent diagnostic testing facilities (IDTFs) or physician offices. This is where the payment value for LUMASON (Q0950) can be found at: www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McpPartBDrugAvgSalesPrice/2017ASPFiles.html.

Medicare Physician Fee Schedule (MPFS)
Find out physician payment for specific geographic locations in the country for different procedures. This schedule provides: global (G), technical (TC), and professional (26) component payment rates. See MEDICARE NATIONAL AVERAGE PAYMENTS FOR PHYSICIAN OFFICE & IDTFs chart for echocardiography and ultrasound procedures covered on page 14 of this guide. To find out more information on specific locations visit: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSLookups/index.html?redirect=/pfslookups.

INDICATIONS AND USAGE

LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CPT® & HCPCS codes

The following chart displays codes for procedures using LUMASON.

<table>
<thead>
<tr>
<th>CPT®/HCPCS codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q9950</td>
<td>Sulfur hexafluoride lipid microspheres, per mL. There are 5 mL per single-use vial of LUMASON. The Pass-Through payment for LUMASON is effective until December 31, 2017. The ASP or payment rate for the Pass-Through payment is updated on a quarterly basis in the Medicare Addendum B. LUMASON is paid separately in the physician office/IDTF; refer to the Medicare Part B drug ASP file for the current payment value. Links are provided to find the quarterly update on page 9 of this guide. Starting Jan. 1, 2017, CMS is requiring the use of the JW modifier to indicate the number of mL or units discarded for single-use vial drugs. Visit <a href="http://www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/HospitalOutpatientpps/Addendum-A-and-Addendum-B-Updates.html">www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/HospitalOutpatientpps/Addendum-A-and-Addendum-B-Updates.html</a> for more information. Note that LUMASON, HCPCS code Q9950, is always separately coded along with the appropriate procedure performed as defined below.</td>
</tr>
</tbody>
</table>

Echocardiography procedure codes


933xx series and C-8921-30 series

- Note that the C-codes series is for HOPPS only.
- Some commercial payers may accept C-codes. Providers need to check with their contracts.

Ultrasonography of the liver

- C9744 Ultrasound, abdominal, with contrast, for HOPPS only; some commercial payers may accept the C-code.
- 76700 Ultrasound, abdominal w/real time documentation, complete.
- 76705 Ultrasound, abdominal w/real time documentation, limited.

Ultrasonography of urinary tract for vesicoureteral reflux

- C9744 Ultrasound, abdominal, with contrast, for HOPPS only; some commercial payers may accept the C-code.
- 76770 Ultrasound, retroperitoneal, real time with image documentation, complete.
- 76775 Ultrasound, retroperitoneal, real time with image documentation, limited.

Other codes that may apply based on setting and payer

- 96374 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single, or initial substance/drug. Not billable by the physician. Not appropriate with modifiers -26 or TC. Applicable if the physician provider bills from a place of service (11).

INDICATIONS AND USAGE

LUMASON is an ultrasound contrast agent indicated for use:
- In echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms.
- In ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
- In ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients.

CONTRAINDICATIONS

LUMASON is contraindicated in patients with:
- History of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
Medicare National Payment Rates for HOPPS

Medicare National Payment Rates: echocardiography HCPCS C-code series for Medicare—HOPPS

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long-Description HCPCS</th>
<th>2017 HOPPS National Payment Rate - HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8921</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8922</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8923</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8924</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study</td>
<td>$426.52</td>
</tr>
<tr>
<td>C8925</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8926</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8927</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8928</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8929</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography</td>
<td>$656.91</td>
</tr>
<tr>
<td>C8930</td>
<td>Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision</td>
<td>$656.91</td>
</tr>
</tbody>
</table>

**INDICATIONS AND USAGE**

LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS**

LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

**IMPORTANT SAFETY INFORMATION**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Medicare National Payment Rates for HOPPS (cont’d)

Medicare National Payment Rates: echocardiography CPT® codes for non-Medicare and commercial payers—HOPPS

INDICATIONS AND USAGE

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)].


The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Medicare National Payment Rates for HOPPS

Ultrasonography of the liver: Medicare National Payment Rates HOPPS4

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Long-description CPT®</th>
<th>2017 HOPPS National Payment Rate - CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9744</td>
<td>Ultrasound, abdominal, with contrast, for HOPPS only, some commercial payers may accept the C-code</td>
<td>$265.02</td>
</tr>
<tr>
<td>76700</td>
<td>Ultrasound, abdominal, w/real-time documentation, complete</td>
<td>$112.73</td>
</tr>
<tr>
<td>76705</td>
<td>Ultrasound, abdominal w/real-time documentation, limited</td>
<td>$112.73</td>
</tr>
</tbody>
</table>

Ultrasonography of the urinary tract: Medicare National Payment Rates HOPPS4,5

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Long-description CPT®</th>
<th>2017 HOPPS National Payment Rate - CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9744</td>
<td>Ultrasound, abdominal, with contrast, for HOPPS only, some commercial payers may accept the C-code</td>
<td>$265.02</td>
</tr>
<tr>
<td>76770</td>
<td>Ultrasound, retroperitoneal, real time with image documentation, complete</td>
<td>$112.73</td>
</tr>
<tr>
<td>76775</td>
<td>Ultrasound, retroperitoneal, real time with image documentation, limited</td>
<td>$112.73</td>
</tr>
</tbody>
</table>

Echocardiography: Cross Walk Codes Without and With Contrast4,6

<table>
<thead>
<tr>
<th>CPT</th>
<th>without contrast</th>
<th>with contrast</th>
<th>C-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>93303</td>
<td></td>
<td></td>
<td>C8921</td>
</tr>
<tr>
<td>93304</td>
<td></td>
<td></td>
<td>C8922</td>
</tr>
<tr>
<td>93306</td>
<td></td>
<td></td>
<td>C8929</td>
</tr>
<tr>
<td>93307</td>
<td></td>
<td></td>
<td>C8923</td>
</tr>
<tr>
<td>93308</td>
<td></td>
<td></td>
<td>C8924</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CPT</th>
<th>without contrast</th>
<th>with contrast</th>
<th>C-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>93312</td>
<td></td>
<td></td>
<td>C8925</td>
</tr>
<tr>
<td>93315</td>
<td></td>
<td></td>
<td>C8926</td>
</tr>
<tr>
<td>93318</td>
<td></td>
<td></td>
<td>C8927</td>
</tr>
<tr>
<td>93350</td>
<td></td>
<td></td>
<td>C8928</td>
</tr>
<tr>
<td>93351</td>
<td></td>
<td></td>
<td>C8930</td>
</tr>
</tbody>
</table>

**INDICATIONS AND USAGE1**

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS1**

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

**IMPORTANT SAFETY INFORMATION1**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
Medicare National Average Payments for physician office & IDTFs®

Echocardiography

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Short descriptor</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>93303 TC</td>
<td>TTE limited congenital</td>
<td>$175.14</td>
</tr>
<tr>
<td>93303 26</td>
<td>TTE limited congenital</td>
<td>$64.96</td>
</tr>
<tr>
<td>93303 G</td>
<td>TTE limited congenital</td>
<td>$240.10</td>
</tr>
<tr>
<td>93304 TC</td>
<td>TTE limited</td>
<td>$120.23</td>
</tr>
<tr>
<td>93304 26</td>
<td>TTE limited</td>
<td>$37.32</td>
</tr>
<tr>
<td>93304 G</td>
<td>TTE limited</td>
<td>$157.55</td>
</tr>
<tr>
<td>93306 TC</td>
<td>TTE comp, Dop, CF</td>
<td>$166.52</td>
</tr>
<tr>
<td>93306 26</td>
<td>TTE comp, Dop, CF</td>
<td>$64.96</td>
</tr>
<tr>
<td>93306 G</td>
<td>TTE comp, Dop, CF</td>
<td>$231.48</td>
</tr>
<tr>
<td>93307 TC</td>
<td>TTE comp, w/o Dop, CF</td>
<td>$85.77</td>
</tr>
<tr>
<td>93307 26</td>
<td>TTE comp, w/o Dop, CF</td>
<td>$45.94</td>
</tr>
<tr>
<td>93307 G</td>
<td>TTE comp, w/o Dop, CF</td>
<td>$131.71</td>
</tr>
<tr>
<td>93308 TC</td>
<td>TTE F/U or limited</td>
<td>$100.49</td>
</tr>
<tr>
<td>93308 26</td>
<td>TTE F/U or limited</td>
<td>$26.20</td>
</tr>
<tr>
<td>93308 G</td>
<td>TTE F/U or limited</td>
<td>$126.69</td>
</tr>
<tr>
<td>93312 TC</td>
<td>TEE place acq, int, rep.</td>
<td>$138.17</td>
</tr>
<tr>
<td>93312 26</td>
<td>TEE place acq, int, rep.</td>
<td>$111.61</td>
</tr>
<tr>
<td>93312 G</td>
<td>TEE place acq, int, rep.</td>
<td>$248.79</td>
</tr>
<tr>
<td>93314 TC</td>
<td>TEE acq, inter, report</td>
<td>$146.78</td>
</tr>
<tr>
<td>93314 26</td>
<td>TEE acq, inter, report</td>
<td>$93.31</td>
</tr>
<tr>
<td>93314 G</td>
<td>TEE acq, inter, report</td>
<td>$240.10</td>
</tr>
</tbody>
</table>

Ultrasoundography of the liver®

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Short descriptor</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>76700 TC</td>
<td>Ultrasound of abdomen, complete</td>
<td>$83.62</td>
</tr>
<tr>
<td>76700 26</td>
<td>Ultrasound of abdomen, complete</td>
<td>$41.27</td>
</tr>
<tr>
<td>76700 G</td>
<td>Ultrasound of abdomen, complete</td>
<td>$124.89</td>
</tr>
<tr>
<td>76705 TC</td>
<td>Ultrasound of abdomen, limited</td>
<td>$63.16</td>
</tr>
<tr>
<td>76705 26</td>
<td>Ultrasound of abdomen, limited</td>
<td>$30.15</td>
</tr>
<tr>
<td>76705 G</td>
<td>Ultrasound of abdomen, limited</td>
<td>$93.31</td>
</tr>
</tbody>
</table>

Ultrasoundography of the urinary tract – VUR®

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Short descriptor</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>76770 TC</td>
<td>Ultrasound, retroperitoneal complete</td>
<td>$77.88</td>
</tr>
<tr>
<td>76770 26</td>
<td>Ultrasound, retroperitoneal, complete</td>
<td>$37.38</td>
</tr>
<tr>
<td>76770 G</td>
<td>Ultrasound, retroperitoneal, complete</td>
<td>$115.56</td>
</tr>
<tr>
<td>76775 TC</td>
<td>Ultrasound, retroperitoneal, limited</td>
<td>$30.15</td>
</tr>
<tr>
<td>76775 26</td>
<td>Ultrasound, retroperitoneal, limited</td>
<td>$29.43</td>
</tr>
<tr>
<td>76775 G</td>
<td>Ultrasound, retroperitoneal, limited</td>
<td>$59.58</td>
</tr>
</tbody>
</table>

VUR=vesicoureteral reflux.

INDICATIONS AND USAGE®

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS®

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION®

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)].

Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Please see full Prescribing Information including boxed WARNING at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
PHYSICIAN OFFICE & IDTF BILLING

LUMASON is paid separately by Medicare Part B
When an echocardiogram or other type of ultrasound exam is performed in the physician’s office or IDTF, LUMASON (Q9950) is paid separately by Medicare Part B and is reported along with the appropriate CPT® procedure code. LUMASON (Q9950) contrast agent payment amounts are based on ASP (average selling price + 6%) and are reimbursed at the discretion of the Local Medicare Contractors (MAC). Payment rates are adjusted quarterly; please refer to the Medicare Part B ASP file at: www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html.

LUMASON is a single-use vial. Medicare allows reimbursement for the amount injected and the amount discarded for single-use vials. Effective January 1, 2017, the JW modifier is required on the claim form. The JW modifier documents the amount of a single-use vial that is discarded. LUMASON contains a total of 5 mL. For more information: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf.

The Medicare National Average payment rates for global (G), technical (TC), and professional (26) for the procedures are listed in MEDICARE NATIONAL AVERAGE PAYMENTS FOR PHYSICIAN OFFICE & IDTF chart in the CODING section of this guide.

Commercial payers usually reimburse contrasts agents separately in the physician office and IDTF setting. Providers need to verify their contracts to confirm coding, coverage, and payment amounts.

INDICATIONS AND USAGE
LUMASON is an ultrasound contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS
LUMASON is contraindicated in patients with:
• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATIONS AND USAGE
LUMASON is an ultrasound contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS
LUMASON is contraindicated in patients with:
• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)].
Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Hospital in-patient billing: Medicare Severity Adjusted Diagnosis Related Groups (MS-DRG)

ICD-10 procedure codes are used for in-patient billing. They indicate the surgical and/or diagnostic procedures performed on the patient. These codes, in combination with diagnosis codes, help determine the assignment to a MS-DRG payment category under Medicare and other payment systems. Payment in the hospital is determined by the MS-DRG. Under this system, a hospital is paid at a predetermined specific rate for each Medicare discharge. Fixed reimbursement is established for hospital services based on the patient diagnosis and is paid regardless of the actual cost the hospital incurs in providing the services. Ultrasound exams and contrast agents are part of the MS-DRG payment.

Coverage: Medicare National Coverage Decisions (NCD)

Echocardiography is included in the Medicare NCD for ultrasound and is limited. There are Medicare Local Coverage Decisions (LCDs) for echocardiography with contrast. The echocardiography LCDs can be found on the CMS website at: www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx.

The Medicare National Coverage Determination (NCD) for ultrasound is non-specific. Abdominal and retroperitoneal ultrasound are covered if medically appropriate.

Medicare National Coverage Determinations Manual, Chapter 1, Part 4, Section 220.5

INDICATIONS AND USAGE

LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)].
Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
How we support you
The Bracco Reimbursement Hotline is here to support you for all your reimbursement needs.

- HCPCS codes for products
- CPT® and HCPCS codes for procedures
- Medicare payments

For more information on reimbursement, contact the Bracco Reimbursement hotline at: Askbracco@reimbursement.bracco.com

Or call: 1-800-349-1388
Monday–Friday: 9:00 AM–6:00 PM Eastern Time

References:
1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. full Prescribing Information. Monroe Twp, NJ: Bracco Diagnostics Inc., December 2016.

INDICATIONS AND USAGE
LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINdications
LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)].

- Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATIONS AND USAGE
LUMASON is an ultrasonic contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS
LUMASON is contraindicated in patients with:
• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc.

Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446
©2017 Bracco Diagnostics Inc. All Rights Reserved.